NASDAQ:ATRS - Antares Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.60
  • Forecasted Upside: 0.18 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.59
+0 (0.00%)

This chart shows the closing price for ATRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Antares Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRS

Analyst Price Target is $5.60
▲ +0.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Antares Pharma in the last 3 months. The average price target is $5.60, with a high forecast of $5.60 and a low forecast of $5.60. The average price target represents a 0.18% upside from the last price of $5.59.

This chart shows the closing price for ATRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Antares Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2022LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
4/14/2022Piper SandlerDowngradeOverweight ➝ Neutral$6.00 ➝ $5.60Low
4/14/2022HC WainwrightDowngradeBuy ➝ Neutral$5.60Low
4/14/2022Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
4/13/2022Truist FinancialDowngradeBuy ➝ Hold$7.00 ➝ $5.60Low
2/24/2022HC WainwrightReiterated RatingBuy$5.00High
11/5/2021HC WainwrightLower Price TargetIn-Line ➝ Buy$6.00 ➝ $5.00High
8/6/2021HC WainwrightBoost Price TargetBuy$5.00 ➝ $5.50High
7/16/2021Truist FinancialInitiated CoverageBuy$7.00Medium
5/10/2021HC WainwrightBoost Price TargetBuy$4.50 ➝ $5.00Low
10/1/2020Raymond JamesReiterated RatingBuyMedium
9/15/2020Raymond JamesReiterated RatingBuy$6.00Medium
8/24/2020Raymond JamesReiterated RatingBuyLow
8/17/2020Raymond JamesReiterated RatingBuyHigh
8/10/2020HC WainwrightReiterated RatingBuyLow
6/21/2020Piper SandlerReiterated RatingOverweight$5.00Low
6/21/2020LADENBURG THALM/SH SHReiterated RatingBuy$7.00Low
5/6/2020HC WainwrightLower Price TargetBuy$5.00 ➝ $4.50High
3/4/2020Raymond JamesBoost Price TargetStrong-Buy$5.65 ➝ $6.00High
3/4/2020HC WainwrightReiterated RatingBuy$5.00High
1/24/2020HC WainwrightReiterated RatingBuy$5.00Low
5/6/2019HC WainwrightReiterated RatingBuy$4.50Low
3/4/2019Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$5.25 ➝ $5.65Medium
2/25/2019CowenInitiated CoverageOutperform$3.30 ➝ $1.99High
11/7/2018HC WainwrightReiterated RatingBuy$4.50High
11/6/2018Jefferies Financial GroupBoost Price TargetBuy$8.00Medium
10/2/2018Jefferies Financial GroupBoost Price TargetBuy$7.00High
10/2/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$3.85 ➝ $5.25High
10/1/2018HC WainwrightSet Price TargetBuy$5.00High
8/17/2018Piper Jaffray CompaniesReiterated RatingBuy$4.00Low
8/17/2018HC WainwrightSet Price TargetBuy$5.00Medium
8/8/2018HC WainwrightSet Price TargetBuy$4.00High
5/8/2018HC WainwrightSet Price TargetBuy$4.00Low
3/27/2018HC WainwrightSet Price TargetBuy$4.00High
3/14/2018HC WainwrightSet Price TargetBuy$4.00Medium
2/15/2018HC WainwrightReiterated RatingBuy$4.00Low
11/8/2017HC WainwrightReiterated RatingBuy$3.50N/A
10/23/2017Piper Jaffray CompaniesSet Price TargetBuy$3.00N/A
10/23/2017HC WainwrightLower Price TargetBuy$5.00 ➝ $3.50N/A
10/13/2017HC WainwrightSet Price TargetBuy$5.00N/A
9/10/2017HC WainwrightReiterated RatingBuy$5.00Low
9/8/2017Piper Jaffray CompaniesReiterated RatingBuyLow
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/15/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Antares Pharma logo
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
Read More

Today's Range

Now: $5.59
Low: $5.59
High: $5.59

50 Day Range

MA: $5.59
Low: $5.59
High: $5.59

52 Week Range

Now: $5.59
Low: $3.11
High: $5.60

Volume

4,776 shs

Average Volume

3,291,313 shs

Market Capitalization

$955.06 million

P/E Ratio

23.29

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Antares Pharma?

The following equities research analysts have issued reports on Antares Pharma in the last year: HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, Raymond James, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for ATRS.

What is the current price target for Antares Pharma?

3 Wall Street analysts have set twelve-month price targets for Antares Pharma in the last year. Their average twelve-month price target is $5.60, suggesting a possible upside of 0.2%. Truist Financial Co. has the highest price target set, predicting ATRS will reach $5.60 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $5.60 for Antares Pharma in the next year.
View the latest price targets for ATRS.

What is the current consensus analyst rating for Antares Pharma?

Antares Pharma currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATRS, but not buy more shares or sell existing shares.
View the latest ratings for ATRS.

What other companies compete with Antares Pharma?

How do I contact Antares Pharma's investor relations team?

Antares Pharma's physical mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company's listed phone number is (609) 359-3020 and its investor relations email address is [email protected] The official website for Antares Pharma is www.antarespharma.com. Learn More about contacing Antares Pharma investor relations.